Skip to main content
NCBI home page
Gut logoLink to Gut
. 1973 Aug;14(8):631–636. doi: 10.1136/gut.14.8.631

The metabolism of salicylazosulphapyridine in ulcerative colitis

I The relationship between metabolites and the response to treatment in inpatients

K M Das, M A Eastwood, J P A McManus, W Sircus
PMCID: PMC1412758  PMID: 4147555

Abstract

The metabolism of salicylazosulphapyridine was studied in 16 patients with ulcerative colitis admitted to hospital. The acetylator phenotype was determined on admission. The mean serum concentration (μg/ml) (at steady state eight ± two days in patients responding to treatment) of SASP, total SP, and 5-ASA were 18·7 ± 12·8; 53·7 ± 23·1; and 1 ± 0·9 for slow acetylators and 17·6 ± 7·1; 31 ± 9·0 and 1 ± 0·9 for fast acetylators respectively. Twenty-four hour urinary excretion of SASP, total SP, and 5-ASA were 4·6% ± 3·1; 52% ± 9·6 and 22·3 ± 6·7% of the administered dose respectively.

Serum total SP concentration of 20 to 50 μg/ml appeared to coincide with clinical improvement in the absence of any side effects related to salicylazosulphapyridine. No such relationship could be shown with serum SASP, individual metabolites, or 5-aminosalicyclic acid.

Full text

PDF
631

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BARON J. H., CONNELL A. M., LENNARD-JONES J. E., JONES F. A. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962 May 26;1(7239):1094–1096. doi: 10.1016/s0140-6736(62)92080-9. [DOI] [PubMed] [Google Scholar]
  2. DICK A. P., GRAYSON M. J., CARPENTER R. G., PETRIE A. CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS. Gut. 1964 Oct;5:437–442. doi: 10.1136/gut.5.5.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Das K. M., Eastwood M. A., Macmanus J. P., Sircus W. Salazopyrin metabolism in ulcerative colitis. Gut. 1972 Oct;13(10):840–840. [PubMed] [Google Scholar]
  4. Evans D. A. An improved and simplified method of detecting the acetylator phenotype. J Med Genet. 1969 Dec;6(4):405–407. doi: 10.1136/jmg.6.4.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. HANNGREN A., HANSSON E., SVARTZ N., ULLBERG S. Distribution and metabolism of salicyl-azo-sulfapyridine. II. A study with S35-salicyl-azo-sulfapyridine and S35-sulfapyridine. Acta Med Scand. 1963 Apr;173:391–399. doi: 10.1111/j.0954-6820.1963.tb17422.x. [DOI] [PubMed] [Google Scholar]
  6. Hansson K. A. Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulphapyridine. Acta Pharm Suec. 1973 May;10(2):153–155. [PubMed] [Google Scholar]
  7. Hansson K. A., Sandberg M. Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine. Acta Pharm Suec. 1973 Mar;10(1):87–92. [PubMed] [Google Scholar]
  8. Jalan K. N., Prestcott R. F., Sircus W., Card W. I., McManus J. P., Falconer C. W., Small W. P., Smith A. N., Bruce J. Ulcerative colitis. A clinical study of 399 patients. J R Coll Surg Edinb. 1971 Nov;16(6):338–351. [PubMed] [Google Scholar]
  9. LENNARD-JONES J. E., MISIEWICZ J. J., CONNELL A. M., BARON J. H., JONES F. A. PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION. Lancet. 1965 Jan 23;1(7378):188–189. doi: 10.1016/s0140-6736(65)90973-6. [DOI] [PubMed] [Google Scholar]
  10. Lennard-Jones J. E. Observations on the treatment of colitis. Schweiz Med Wochenschr. 1971 May 22;101(20):701–706. [PubMed] [Google Scholar]
  11. Peppercorn M. A., Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972 Jun;181(3):555–562. [PubMed] [Google Scholar]
  12. Sandberg M., Hansson K. A. Determination of salicylazosulphapyridine in biological materials. Acta Pharm Suec. 1973 May;10(2):107–110. [PubMed] [Google Scholar]
  13. Schröder H., Campbell D. E. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther. 1972 Jul-Aug;13(4):539–551. doi: 10.1002/cpt1972134539. [DOI] [PubMed] [Google Scholar]
  14. Schröder H., Evans D. A. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut. 1972 Apr;13(4):278–284. doi: 10.1136/gut.13.4.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Schröder H., Evans D. A. The polymorphic acetylation of sulphapyridine in man. J Med Genet. 1972 Jun;9(2):168–171. doi: 10.1136/jmg.9.2.168. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES